Skip to main content

Elite Pharmaceuticals, Inc.

corporate_fare Company Profile

Elite Pharmaceuticals, Inc.

ELTP·OTC·Life Sciences·CIK 0001053369

ELITE PHARMACEUTICALS INC is a specialty pharmaceutical company focused on the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company was reincorporated under the laws of the State of Nevada on January 5, 2012. Its strategy involves developing generic versions of controlled-release drug products that have high barriers to entry. ELITE PHARMACEUTICALS INC operates from manufacturing, warehouse, laboratory, and office space located at 135, 144, and 165 Ludlow Avenue in Northvale, NJ, referred to as the Northvale Facility. This facility adheres to Current Good Manufacturing Practice (cGMP) standards and is registered with the United States Drug Enforcement Agency (DEA) for research, development, and manufacturing activities. The company's strategy focuses on several key areas: manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications (ANDAs); developing additional generic pharmaceutical products; advancing other product candidates in its pipeline, including those co-developed with partners; commercially exploiting its products through sales under its own label, licensing and royalty collection, or manufacturing its formulations; and developing new products for sale under its own label, alongside expanding licensing agreements with other pharmaceutical companies, including co-development projects, joint ventures, and other collaborations. ELITE PHARMACEUTICALS INC evaluates opportunities for various drug products, including branded drug products requiring New Drug Applications (NDAs) under Section 505(b)(1) or 505(b)(2) of the Drug Price Competition and Patent Term Restoration Act of 1984, as well as generic drug products requiring ANDAs. The company aims to reduce risk through a diverse product portfolio.

Elite Pharmaceuticals, Inc. (OTC:ELTP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for ELTP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for ELTP spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Elite Pharma Q2 Revenue Climbs 10% to $40.1M, Operating Income Up 21%
  • Elite Q2 Revenue Up 10% to $40.1M, But Six-Month Gross Margin Falls to 41% and Material Weaknesses Persist
  • Elite Pharmaceuticals Q1 FY2027 Revenue Falls 19.5% to $32.4M; Net Income $5.9M
  • Elite Pharmaceuticals Q1 FY2027: Revenue Falls 19.5%, Material Weaknesses Disclosed
  • Elite Pharma Reports 77% Revenue Growth, 151% Operating Income Surge for FY26

Financial Snapshot

Fiscal year ended March 31, 2026
Revenue
$148.87M
Net Income
$44.87M
Diluted EPS
$0.03
Op. Cash Flow
$23.75M
Free Cash Flow
$22.82M
Gross Profit
$75.02M
Operating Income
$49.11M
Cash & Equivalents
$29.8M
Debt / Equity
0.00×
Net Margin
30.1%
Shares Outstanding
1.08B sh
Source: 10-K · filed 2026-06-29 · accession 0001493152-26-031070

Short Interest & Short Volume

2.76 days to cover

FINRA reported short interest of 2,991,818 shares in ELTP as of the October 30, 2026 settlement, a 1.4% decrease from the prior period — about 2.8 days to cover at its recent average daily volume. On November 20, 2026, 61.2% of ELTP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,991,818 shares as of October 30, 2026
Change vs prior period▼ 1.4%
Days to cover2.76 at avg daily volume of 1,084,460
Daily short volume (FINRA facilities)61.2% of 348,366 shares on November 20, 2026
5-day average short volume49.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with E →
$0.3222 -0.52% today
52-week range · as of 2026-11-12 $0.2107 – $0.69
Market cap
$347.19M
Volume
348.3K (0.4× avg)
3-mo avg 777.2K
Live data · 2026-11-21 19:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ELTP - Latest Insights

ELTP
Nov 12, 2026, 4:38 PM EST
Source: TMX Newsfile
Importance Score:
7
Price at Filing: $0.245
Real-time Price: $0.3222 info
Change: +$0.0772 (+32%) info
Market Cap: $347.193M info
ELTP
Nov 12, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.245
Real-time Price: $0.3222 info
Change: +$0.0772 (+32%) info
Market Cap: $347.193M info
ELTP
Aug 13, 2026, 4:17 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3585
Real-time Price: $0.3222 info
Change: -$0.0363 (-10%) info
Market Cap: $347.193M info
ELTP
Aug 13, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.3585
Real-time Price: $0.3222 info
Change: -$0.0363 (-10%) info
Market Cap: $347.193M info
ELTP
Jun 29, 2026, 4:29 PM EDT
Source: TMX Newsfile
Importance Score:
9
Price at Filing: $0.395
Real-time Price: $0.3222 info
Change: -$0.0728 (-18%) info
Market Cap: $347.193M info
ELTP
Jun 29, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $0.395
Real-time Price: $0.3222 info
Change: -$0.0728 (-18%) info
Market Cap: $347.193M info
ELTP
Jun 15, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.339175
Real-time Price: $0.3222 info
Change: -$0.016975 (-5%) info
Market Cap: $347.193M info
ELTP
Jun 15, 2026, 7:00 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $0.339175
Real-time Price: $0.3222 info
Change: -$0.016975 (-5%) info
Market Cap: $347.193M info
ELTP
Jun 01, 2026, 7:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.344
Real-time Price: $0.3222 info
Change: -$0.0218 (-6%) info
Market Cap: $347.193M info
ELTP
Jun 01, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.344
Real-time Price: $0.3222 info
Change: -$0.0218 (-6%) info
Market Cap: $347.193M info
ELTP
Apr 02, 2026, 8:13 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.350
Real-time Price: $0.3222 info
Change: -$0.0278 (-8%) info
Market Cap: $347.193M info
ELTP
Apr 02, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.350
Real-time Price: $0.3222 info
Change: -$0.0278 (-8%) info
Market Cap: $347.193M info
ELTP
Feb 17, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.441
Real-time Price: $0.3222 info
Change: -$0.1188 (-27%) info
Market Cap: $347.193M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets